Vaderis is developing engasertib (VAD044), an investigational once-daily oral selective allosteric AKT1/2 inhibitor intended to treat hereditary hemorrhagic telangiectasia (HHT). The company has advanced engasertib into pivotal development following positive proof-of-concept and long-term extension data published in The New England Journal of Medicine. Vaderis has initiated HEROIC, a global Phase 3 randomized, double-blind, placebo-controlled study enrolling patients across North America, South America and Europe. The company intends to use proceeds from its $152 million Series B to support operations through regulatory submissions and potential U.S. approval. Vaderis is headquartered in Basel, Switzerland, with a U.S. subsidiary in Lincolnshire, Illinois. The company positions engasertib as a potential first approved therapy specifically developed for people living with HHT.

Total raised

$171M

Funding rounds

2

Latest round

Series B

Latest activity

Aug 2026